In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer Outcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty: Laura M. Spring, MD Breast Medical Oncologist Mass General Hospital Cancer Center Harvard Medical School Boston, Massachusetts Shipra Gandhi, MD, MS Associate Professor Director, Breast Translational Research Glenn Family Breast Center Winship Cancer Institute of Emory University Atlanta, Georgia Resources: To access the interactive patient cases associated with this podcast discussion, please visit the program page , to access a recording from a live webinar , and an interactive decision support tool on this topic. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
